Crizotinib: from discovery to accelerated development to front-line treatment

Lung, Respiratory and Thoracic Cancer

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)

J Thorac Oncol.

Spigel DR, Reynolds C, Waterhouse D, Garon EB, Chandler J, Babu S, Thurmes P, Spira A, Jotte R, Zhu J, Lin WH, Blumenschein G Jr.

doi: 10.1016/j.jtho.2018.02.022.

Lung, Respiratory and Thoracic CancerLymphoma

Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

BMC Cancer.

Zhou J, Zheng J, Zhang X, Zhao J, Zhu Y, Shen Q, Wang Y, Sun K, Zhang Z, Pan Z, Shen Y, Zhou J

doi: 10.1186/s12885-017-3720-8.

Leukemia

Front-line treatment of CLL in the era of novel agents

Cancer Treat Rev.

Robak T, Stilgenbauer S, Tedeschi A

doi: 10.1016/

Leukemia

Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials

Leukemia.

Al-Sawaf O, Robrecht S, Bahlo J, Fink AM, Cramer P, V Tresckow J, Lange E, Kiehl M, Dreyling M, Ritgen M, Dürig J, Tausch E, Schneider C, Stilgenbauer S, Wendtner CM, Fischer K, Goede 5th, Hallek M, Eichhorst B

doi: 10.1038/s41375-020-0797-x.

Lung Cancer

Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.

1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.

Genitourinary Cancer

Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry

Clin Genitourin Cancer.

Stenner F, Rothschild SI, Betticher D, Caspar C, Morant R, Popescu R, Rauch D, Huber U, Zenhäusern R, Rentsch C, Cathomas R

doi: 10.1016/j.clgc.2017.08.003.

Gastrointestinal CancerLung, Respiratory and Thoracic Cancer

Mini Review: Erlotinib as first-line treatment for NSCLC – an overview of the data currently available

Wolf-Dieter Janthur FMH specialist in oncology Senior physician, Aarau Canton Hospital Consultant doctor to Muri Hospital

Leukemia

Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial

doi: 10.1002/ajh.25261.

Gastrointestinal Cancer

Impact of prior bevacizumab treatment on VEGF-A and PlGF levels and outcome following second-line aflibercept treatment: Biomarker post hoc analysis of the VELOUR trial

Clin Cancer Res.

Van Cutsem E, Paccard C, Chiron M, Tabernero J

doi: 10.1158/1078-0432.CCR-19-1985.

Related content

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)

Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

Front-line treatment of CLL in the era of novel agents

Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials

Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.

Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry

Mini Review: Erlotinib as first-line treatment for NSCLC – an overview of the data currently available

Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial

Impact of prior bevacizumab treatment on VEGF-A and PlGF levels and outcome following second-line aflibercept treatment: Biomarker post hoc analysis of the VELOUR trial